ArticleBMC nephrology2025
Design and rationale for a pilot trial of D-alanine supplementation to reduce the triglyceride to high-density lipoprotein cholesterol ratio in patients with chronic kidney disease.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundChronic kidney disease (CKD) is an increasingly prevalent disease that adversely affects patients' quality of life and medical expenses. While its progression is linked to lifestyle-related diseases, its association with dyslipidemia remains unclear. We previously showed a significant association between a high triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio and CKD progression and cardiovascular disease in CKD patients. Recent reports indicate that D-alanine regulates circadian rhythms, participates in gluconeogenesis, and exhibits renoprotective effects. This study will investigate whether D-alanine has a beneficial effect on the TG/HDL-C ratio in CKD patients.
methodsThis open-label, multicenter, single-arm, exploratory trial will involve 20 CKD patients and last for 10 weeks, including a 2-week run-in, 4-week treatment, and 4-week follow-up period. Patients will be recruited from Nara Medical University and Nara Prefectural General Medical Center. The primary endpoint is the change in fasting TG/HDL-C ratios between baseline and Day 28. Secondary endpoints include changes in fasting TG, HDL-C, low-density lipoprotein cholesterol, aspartate aminotransferase, alanine aminotransferase, glycated hemoglobin A1c, systolic and diastolic blood pressure, proteinuria, estimated glomerular filtration rate, and body weight between baseline and Day 28. The study will summarize absolute measurements and changes using descriptive statistics, confidence intervals, and line graphs showing means ± confidence intervals. A two-tailed significance level of p < 0.05 will be used. DISCUSSION: This exploratory study aims to evaluate the efficacy and safety of D-alanine for treating dyslipidemia in CKD patients, and may provide insights that help reduce the risk of cardiorenal events in CKD patients.
trial registrationThis protocol was approved by the Clinical Trial Review Board of Nara Medical University Clinical Research Review Committee (CRB5200002) on February 5, 2025, and is available to the public on the website of the Japan Registry of Clinical Trials on December 18, 2024 (jRCTs051240262).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.